Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 1976;47:106-112
© 1976 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dickey, R. P.
Right arrow Articles by Stone, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dickey, R. P.
Right arrow Articles by Stone, S. C.

PROGESTATIONAL POTENCY OF ORAL CONTRACEPTIVES

Richard P. Dickey, MD, PhD, FACOG and Sergio C. Stone, MD

From the Section of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Louisiana State University, New Orleans, Louisiana

The induction of glycogen deposition as subnuclear vacuoles was found to be a better method in estimating Progestational potency of individual progestins than the delay of menses assay. Norgestrel was the most potent progestin in all assays. The progestational potency of oral contraceptives was estimated by multiplying potency of individual progestins by their dose. Combination oral contraceptives containing norgestrel were in the mid range of progestational potency because of the relatively higher potency of their progestin. The progestational potency of the norethindrone "mini" pill was compared with that of the norethindrone low-progestogen combination pill and the sequential pill over a 28-day cycle, and no appreciable difference was found.




This article has been cited by other articles:


Home page
 Obstet GynecolHome page
G. Lurie, P. Thompson, K. E. McDuffie, M. E. Carney, K. Y. Terada, and M. T. Goodman
Association of Estrogen and Progestin Potency of Oral Contraceptives With Ovarian Carcinoma Risk
Obstet. Gynecol., March 1, 2007; 109(3): 597 - 607.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
J. B. Greer, F. Modugno, G. O. Allen, and R. B. Ness
Androgenic Progestins in Oral Contraceptives and the Risk of Epithelial Ovarian Cancer
Obstet. Gynecol., April 1, 2005; 105(4): 731 - 740.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
C. Bouchard, J. Brisson, M. Fortier, C. Morin, and C. Blanchette
Use of Oral Contraceptive Pills and Vulvar Vestibulitis: A Case-Control Study
Am. J. Epidemiol., August 1, 2002; 156(3): 254 - 261.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
R. B. Ness, J. Ann Grisso, J. Klapper, J. J. Schlesselman, S. Silberzweig, R. Vergona, M. Morgan, J. E. Wheeler, and and the SHARE Study Group
Risk of Ovarian Cancer in Relation to Estrogen and Progestin Dose and Use Characteristics of Oral Contraceptives
Am. J. Epidemiol., August 1, 2000; 152(3): 233 - 241.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1976 by the American College of Obstetricians and Gynecologists.